Procavea develops protein‑based molecular delivery platforms that enable nonviral delivery of RNA therapeutics. Their engineered protein cages protect and transport RNA payloads, addressing stability and targeting challenges in gene‑editing and vaccine applications. The technology also supports medical imaging and enzymatic modification, expanding its utility across biotech and diagnostic markets.
Funding
Funding not disclosed
Founders
Product
Problem
Current drug delivery systems often lack the precision needed to effectively target specific tissues or cells, leading to inefficient therapeutic action and potential off-target effects. This is particularly challenging for RNA and small molecule therapeutics, which can be unstable or poorly absorbed by target cells.
Solution
Procavea Biotech has developed a nonviral protein cage platform designed to enhance the targeted delivery of RNA and small molecule therapeutics. These protein cages improve the bioavailability and efficacy of therapeutics by encapsulating and protecting the drug payload, facilitating targeted delivery to specific cells or tissues. The platform's modular design allows for customization to accommodate various therapeutic payloads and targeting ligands, enabling tailored drug delivery solutions. By improving drug delivery, Procavea's technology aims to improve treatment outcomes and reduce side effects.
Target Audience
Procavea's primary customers are pharmaceutical companies and research institutions developing RNA and small molecule therapeutics, seeking improved drug delivery systems for enhanced efficacy and safety.
Features
- Customizable protein cage architecture for encapsulating diverse therapeutic payloads
- Surface modification with targeting ligands for cell-specific delivery
- Enhanced stability and protection of RNA and small molecule drugs
- Improved bioavailability and reduced off-target effects
- Modular design for tailored drug delivery solutions